NHS rolls out ‘life-changing’ pill to help MS patients walk more easily

Thousands of patients living with multiple sclerosis (MS) across England gained access to a new medicinal option to improve mobility. The National Health Service announced that fampridine, a twice-daily pill, is now routinely available for eligible adults. The introduction of the drug marks a shift in how the health service manages the neurological condition, moving beyond traditional reliance on physiotherapy, walking aids, and foot support devices.

MS is an incurable autoimmune disease characterized by damage to nerves within the brain and spinal cord. This damage frequently disrupts the transmission of electrical signals, resulting in symptoms such as muscle cramps, fatigue, dizziness, and significant challenges with balance and coordination. Fampridine, also referred to as Fampyra, functions as a signal booster to help restore those electrical pulses along damaged pathways, which can facilitate better muscle function.

Related imagery

Clinical trials have shown that the treatment improved walking speed in 43% of patients, while also assisting others in remaining on their feet for longer periods. Eligibility is determined by an assessment of a patient's Expanded Disability Status Scale (EDSS) score, a standard metric used by clinicians to monitor the progression of MS-related disability.

Eligibility and Treatment Process

The NHS has established specific parameters for patients who may benefit from the drug:

• Patients must have an EDSS score between 4 and 7.
• A score of 4 corresponds to individuals who can walk without an aid or rest for around 500 metres.
• A score of 7 describes patients who use wheelchairs or are unable to walk further than five metres.

The introduction of the drug involves a trial period for each patient. Before beginning the medication, individuals undergo an initial assessment of their walking ability. They then take the twice-daily pill for two to four weeks. A second assessment follows to determine if the patient has experienced a clear benefit. Those who demonstrate progress are permitted to continue the treatment, with the expectation of regular reviews to ensure the medication remains effective.

According to Lbc and other reporting, officials estimate that approximately 5,000 patients will be eligible for the treatment within the first year of the rollout. While the medication has a list price, the NHS has utilized collective bargaining to negotiate a confidential discount.

Perspectives on the Rollout

The move brings access in England into alignment with other parts of the United Kingdom, where the drug has been available in Wales since 2019 and in Scotland since 2020.

"Walking difficulties can have a huge impact on the freedom and independence of people with MS, so this signal-boosting pill could be life-changing for thousands of patients. Fampridine helps electrical messages travel along nerves damaged by MS, giving people the chance to walk more easily and helping them be more mobile to do more of the everyday things that matter to them."

Professor Frankie Swords, NHS national medical director, via Mirror

For some, the availability of the drug on the NHS is a significant relief. Aysen Slack, 65, of Eastbourne, previously sourced the medication privately but was forced to cease treatment due to the high financial cost. Fampridine seemed to be working well for me, but paying for the medication was a significant expense and I could not keep doing that forever. So I had to make the difficult decision to stop taking it. My mobility has decreased a lot and even in my flat I have to use sticks now. It would make a huge difference to my life if I were able to improve my walking.

The policy development was spearheaded by the Clinical Priorities Advisory Group, which evaluates specialized treatments based on patient benefit and value for money. Ceri Smith, head of policy and evidence at the MS Society, noted that while the approval is a welcome development for the estimated 120,000 people living with MS in England, implementation remains a priority.

"It’s vital that MS services now have the support they need to make fampridine available to all people with MS who could benefit from it, regardless of where in England they live."

Ceri Smith, head of policy and evidence at the MS Society, via LBC

Professor James Palmer, National Medical Director for Specialised Services at NHS England, emphasized that for patients who have long relied solely on physical aids, this development represents a distinct shift in care options.